Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14143453 | 0.87 | HSD11B1 (0.60) | HSD11B1ALDH1A1MCOLN3 | |
| SCHEMBL4697308 | 0.86 | HSD11B1 (0.59) | HSD11B1ALDH1A1MCOLN3SIGMAR1 | |
| SCHEMBL4698937 | 0.83 | HSD11B1 (0.56) | HSD11B1ALDH1A1MCOLN3 | |
| SCHEMBL4697482 | 0.83 | HSD11B1 (0.61) | HSD11B1ALDH1A1MCOLN3LMNA | |
| SCHEMBL4510178 | 0.83 | HSD11B1 (0.71) | HSD11B1ALDH1A1MCOLN3SIGMAR1 | |
| SCHEMBL4697453 | 0.81 | HSD11B1 (0.57) | HSD11B1ALDH1A1MCOLN3 | |
| SCHEMBL4523952 | 0.80 | HSD11B1 (0.64) | HSD11B1ALDH1A1SIGMAR1 | |
| SCHEMBL14143454 | 0.78 | HSD11B1 (0.61) | HSD11B1ALDH1A1MCOLN3LMNA | |
| SCHEMBL4697099 | 0.78 | HSD11B1 (0.53) | HSD11B1ALDH1A1MCOLN3 | |
| SCHEMBL3548929 | 0.78 | HSD11B1 (0.71) | HSD11B1ALDH1A1MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | claimed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | claimed |
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1830841-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068992-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885ALDH1A1 119/4885MCOLN3 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.